» Articles » PMID: 34885241

Multifaceted Roles of Chemokines and Chemokine Receptors in Tumor Immunity

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Dec 10
PMID 34885241
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Various immune cells are involved in host tumor immune responses. In particular, there are many T cell subsets with different roles in tumor immunity. T-helper (Th) 1 cells are involved in cellular immunity and thus play the major role in host anti-tumor immunity by inducing and activating cytotoxic T lymphocytes (CTLs). On the other hand, Th2 cells are involved in humoral immunity and suppressive to Th1 responses. Regulatory T (Treg) cells negatively regulate immune responses and contribute to immune evasion of tumor cells. Th17 cells are involved in inflammatory responses and may play a role in tumor progression. However, recent studies have also shown that Th17 cells are capable of directly inducting CTLs and thus may promote anti-tumor immunity. Besides these T cell subsets, there are many other innate immune cells such as dendritic cells (DCs), natural killer (NK) cells, and myeloid-derived suppressor cells (MDSCs) that are involved in host immune responses to cancer. The migratory properties of various immune cells are critical for their functions and largely regulated by the chemokine superfamily. Thus, chemokines and chemokine receptors play vital roles in the orchestration of host immune responses to cancer. In this review, we overview the various immune cells involved in host responses to cancer and their migratory properties regulated by the chemokine superfamily. Understanding the roles of chemokines and chemokine receptors in host immune responses to cancer may provide new therapeutic opportunities for cancer immunotherapy.

Citing Articles

Targeted editing of CCL5 with CRISPR-Cas9 nanoparticles enhances breast cancer immunotherapy.

Yan W, Wang S, Zhu L, Yu X, Li J Apoptosis. 2025; .

PMID: 39870938 DOI: 10.1007/s10495-024-02032-6.


Analysis of changes in the chemokine CXC ligand 13 in serum and cerebrospinal fluid of patients with neuromyelitis optica.

Zhou J, Luo S, Yao X, Li H, Wen Y Sci Rep. 2025; 15(1):2113.

PMID: 39814995 PMC: 11735840. DOI: 10.1038/s41598-025-85650-7.


The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.

Ahuja S, Zaheer S Korean J Clin Oncol. 2025; 20(2):51-73.

PMID: 39778508 PMC: 11717579. DOI: 10.14216/kjco.24009.


Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy.

Newman M Front Immunol. 2024; 15:1462221.

PMID: 39606250 PMC: 11599860. DOI: 10.3389/fimmu.2024.1462221.


An Increase in the Chemokine Mediators (CCL28 and CCR10) Associated with the Progression of Oral Squamous Cell Carcinoma: A Cross-Sectional Investigation.

Mehta M, Gupta S, Fatima T, Selvam R, Chandra S, Singh D Indian J Otolaryngol Head Neck Surg. 2024; 76(6):5717-5724.

PMID: 39559102 PMC: 11569321. DOI: 10.1007/s12070-024-05072-1.


References
1.
Takegawa S, Jin Z, Nakayama T, Oyama T, Hieshima K, Nagakubo D . Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder. Cancer Sci. 2008; 99(2):296-302. PMC: 11158311. DOI: 10.1111/j.1349-7006.2007.00687.x. View

2.
Marchica V, Toscani D, Corcione A, Bolzoni M, Storti P, Vescovini R . Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients. Cancers (Basel). 2019; 11(3). PMC: 6469019. DOI: 10.3390/cancers11030321. View

3.
Dillon S, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell S . Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004; 5(7):752-60. DOI: 10.1038/ni1084. View

4.
Liu W, Wei X, Li L, Wu X, Yan J, Yang H . CCR4 mediated chemotaxis of regulatory T cells suppress the activation of T cells and NK cells via TGF-β pathway in human non-small cell lung cancer. Biochem Biophys Res Commun. 2017; 488(1):196-203. DOI: 10.1016/j.bbrc.2017.05.034. View

5.
Cohen E, Pishvaian M, Shepard D, Wang D, Weiss J, Johnson M . A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. J Immunother Cancer. 2019; 7(1):342. PMC: 6894203. DOI: 10.1186/s40425-019-0815-6. View